Evaluation of 68Ga-DOTATOC PET/CT-enterography for the Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel

What this Trial Is About

Neuroendocrine tumors of the small intestine (Si-NENs) are relatively rare cancers. Surgical removal is currently the only curative option for early-stage disease, but its role in advanced metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is still debated. Accurate staging and assessment of tumor burden are critical for determining the correct disease stage and guiding appropriate treatment. A key feature of these tumors is the presence of somatostatin receptors, which can be targeted with special radiolabeled peptides for imaging purposes. This study evaluates the use of a specific imaging technique called 68Ga-DOTATOC PET/CT-enterography to detect primary lesions and multifocal tumors in the small bowel neuroendocrine tumors. Participants undergo this imaging procedure, which uses a radioactive tracer that binds to somatostatin receptors, providing detailed pictures that may be more precise than conventional imaging methods. The study aims to measure how sensitive and specific this imaging test is in identifying these tumors. During the study, participants will have the PET/CT-enterography scan with 68Ga-DOTATOC, and researchers will compare its results to other imaging methods to assess its accuracy. The main outcome is the ability of this imaging to detect the tumors within three months. This helps doctors understand how well this technique works for diagnosing small bowel neuroendocrine tumors and planning treatment. The study is sponsored by the European Institute of Oncology and includes adults aged 18 and older eligible for surgery.

Use of 68Ga-DOTATOC PET/CT-enterography for Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel